Literature DB >> 24899308

The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.

Rachel J Perry1, Varman T Samuel2, Kitt F Petersen3, Gerald I Shulman4.   

Abstract

Non-alcoholic fatty liver disease and its downstream sequelae, hepatic insulin resistance and type 2 diabetes, are rapidly growing epidemics, which lead to increased morbidity and mortality rates, and soaring health-care costs. Developing interventions requires a comprehensive understanding of the mechanisms by which excess hepatic lipid develops and causes hepatic insulin resistance and type 2 diabetes. Proposed mechanisms implicate various lipid species, inflammatory signalling and other cellular modifications. Studies in mice and humans have elucidated a key role for hepatic diacylglycerol activation of protein kinase Cε in triggering hepatic insulin resistance. Therapeutic approaches based on this mechanism could alleviate the related epidemics of non-alcoholic fatty liver disease and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24899308      PMCID: PMC4489847          DOI: 10.1038/nature13478

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  121 in total

1.  Mechanism of insulin resistance in A-ZIP/F-1 fatless mice.

Authors:  J K Kim; O Gavrilova; Y Chen; M L Reitman; G I Shulman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 2.  Cellular mechanisms of insulin resistance.

Authors:  G I Shulman
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

3.  Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.

Authors:  Jason K Kim; Jonathan J Fillmore; Oksana Gavrilova; Lily Chao; Takamasa Higashimori; Hyejeong Choi; Hyo-Jeong Kim; Chunli Yu; Yan Chen; Xianqin Qu; Martin Haluzik; Marc L Reitman; Gerald I Shulman
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

4.  Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4.

Authors:  J K Kim; A Zisman; J J Fillmore; O D Peroni; K Kotani; P Perret; H Zong; J Dong; C R Kahn; B B Kahn; G I Shulman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

5.  The prevalence of weight loss maintenance among American adults.

Authors:  M T McGuire; R R Wing; J O Hill
Journal:  Int J Obes Relat Metab Disord       Date:  1999-12

6.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.

Authors:  J K Kim; J J Fillmore; Y Chen; C Yu; I K Moore; M Pypaert; E P Lutz; Y Kako; W Velez-Carrasco; I J Goldberg; J L Breslow; G I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

7.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Authors:  Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

8.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Authors:  Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

9.  Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

Authors:  Yoshinori Miyazaki; Helen He; Lawrence J Mandarino; Ralph A DeFronzo
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

10.  Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy.

Authors:  Vinaya Simha; Lidia S Szczepaniak; Anthony J Wagner; Alex M DePaoli; Abhimanyu Garg
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

View more
  372 in total

1.  Glycolipid iGb3 feedback amplifies innate immune responses via CD1d reverse signaling.

Authors:  Xingguang Liu; Peng Zhang; Yunkai Zhang; Zheng Wang; Sheng Xu; Yingke Li; Wanwan Huai; Qingqing Zhou; Xiang Chen; Xi Chen; Nan Li; Peng Wang; Yunsen Li; Xuetao Cao
Journal:  Cell Res       Date:  2018-12-04       Impact factor: 25.617

Review 2.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

3.  Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation.

Authors:  Caleb C Lord; Daniel Ferguson; Gwynneth Thomas; Amanda L Brown; Rebecca C Schugar; Amy Burrows; Anthony D Gromovsky; Jenna Betters; Chase Neumann; Jessica Sacks; Stephanie Marshall; Russell Watts; Martina Schweiger; Richard G Lee; Rosanne M Crooke; Mark J Graham; Justin D Lathia; Takuya F Sakaguchi; Richard Lehner; Guenter Haemmerle; Rudolf Zechner; J Mark Brown
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

4.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.

Authors:  Leigh Goedeke; Rachel J Perry; Gerald I Shulman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms.

Authors:  Deyang Yu; Shany E Yang; Blake R Miller; Jaclyn A Wisinski; Dawn S Sherman; Jacqueline A Brinkman; Jay L Tomasiewicz; Nicole E Cummings; Michelle E Kimple; Vincent L Cryns; Dudley W Lamming
Journal:  FASEB J       Date:  2018-01-30       Impact factor: 5.191

6.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

7.  Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.

Authors:  Camella G Wilson; Jennifer L Tran; Derek M Erion; Nicholas B Vera; Maria Febbraio; Ethan J Weiss
Journal:  Endocrinology       Date:  2015-12-09       Impact factor: 4.736

Review 8.  Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen Previs; Takhar Kasumov
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 9.  Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea.

Authors:  Brian D Kent; Walter T McNicholas; Silke Ryan
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

10.  Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.

Authors:  Rebecca J Brown; Areli Valencia; Megan Startzell; Elaine Cochran; Peter J Walter; H Martin Garraffo; Hongyi Cai; Ahmed M Gharib; Ronald Ouwerkerk; Amber B Courville; Shanna Bernstein; Robert J Brychta; Kong Y Chen; Mary Walter; Sungyoung Auh; Phillip Gorden
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.